Literature DB >> 16239841

Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor?

Carmen B Meier1, Refaat A Hegazi, James Aisenberg, Peter E Legnani, Naris Nilubol, Gena M Cobrin, Richard H Duerr, Stephen R Gorfine, Joel J Bauer, David B Sachar, Scott E Plevy.   

Abstract

BACKGROUND: Pouchitis is a frequent complication after ileal pouch-anal anastamosis (IPAA) for ulcerative colitis (UC). The aim of this study was to determine whether genetic polymorphisms in the innate immune receptors toll-like receptor (TLR)4 and caspase activation and recruitment domain family member 15 (CARD15) genes are associated with pouchitis.
METHODS: From a retrospectively ascertained cohort of patients with UC 5 to 12 years after IPAA (n = 101), subjects were classified into 3 groups: no pouchitis (n = 52); 1 to 2 episodes per year (n = 11), and more than 2 episodes per year (n = 38). Single nucleotide polymorphisms in the tlr4 gene (D299G, T399I) were determined by a real-time polymerase chain reaction-based fluorogenic probe technique; and card15 polymorphisms (L1007fsinsC, R702W, G908R) were determined by pyrosequencing.
RESULTS: Pouchitis affected 49% (49/101) of the study population. No correlation between pouchitis and the presence of TLR4 polymorphisms was found. The percentage of patients who harbored CARD15 mutations was significantly higher in patients with pouchitis than in patients without pouchitis (18% versus 8%; P < 0.05); 24% of pouchitis patients with more than 2 episodes per year harbored CARD15 mutations (P < 0.01 compared with the no pouchitis group). The CARD15 insertion mutation L1007fsinsC was present in 14% of patients with pouchitis and in 0% without pouchitis (P < 0.05). All patients who carried L1007fsinsC developed more than 2 episodes per year.
CONCLUSIONS: CARD15 polymorphisms are seen in greater frequency in patients with pouchitis after IPAA for UC. These findings, if borne out in prospective analyses, suggest that CARD15 mutations, particularly L1007fsinsC, may predispose to the development of pouchitis after IPAA for UC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239841     DOI: 10.1097/01.mib.0000186407.25694.cf

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  32 in total

1.  Activation of nuclear factor kappa B inflammatory bowel disease.

Authors:  S Schreiber; S Nikolaus; J Hampe
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

2.  Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice.

Authors:  M F Neurath; S Pettersson; K H Meyer zum Büschenfelde; W Strober
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

3.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

4.  Predominant role of NF-kappa B p65 in the pathogenesis of chronic intestinal inflammation.

Authors:  M F Neurath; S Pettersson
Journal:  Immunobiology       Date:  1997-12       Impact factor: 3.144

5.  The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis.

Authors:  Simon Dai; Teruhisa Hirayama; Sabiha Abbas; Yousef Abu-Amer
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

6.  In vivo pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B activation using a novel gene-targeted enhanced GFP reporter gene mouse.

Authors:  Scott T Magness; Humberto Jijon; Nancy Van Houten Fisher; Ned E Sharpless; David A Brenner; Christian Jobin
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

7.  Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors.

Authors:  R I Scheinman; A Gualberto; C M Jewell; J A Cidlowski; A S Baldwin
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

8.  Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease.

Authors:  M F Neurath; I Fuss; G Schürmann; S Pettersson; K Arnold; H Müller-Lobeck; W Strober; C Herfarth; K H Büschenfelde
Journal:  Ann N Y Acad Sci       Date:  1998-11-17       Impact factor: 5.691

9.  Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa.

Authors:  G Rogler; K Brand; D Vogl; S Page; R Hofmeister; T Andus; R Knuechel; P A Baeuerle; J Schölmerich; V Gross
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.

Authors:  N Auphan; J A DiDonato; C Rosette; A Helmberg; M Karin
Journal:  Science       Date:  1995-10-13       Impact factor: 47.728

View more
  22 in total

Review 1.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

2.  ASCA IgG and CBir antibodies are associated with the development of Crohn's disease and fistulae following ileal pouch-anal anastomosis.

Authors:  Jennifer A Coukos; Lauren A Howard; Janice M Weinberg; James M Becker; Arthur F Stucchi; Francis A Farraye
Journal:  Dig Dis Sci       Date:  2012-02-07       Impact factor: 3.199

3.  Family history of Crohn's disease is associated with an increased risk for Crohn's disease of the pouch.

Authors:  Bo Shen; Feza H Remzi; Jeffrey P Hammel; Bret A Lashner; Charles L Bevins; Ian C Lavery; Jan Wehkamp; Victor W Fazio
Journal:  Inflamm Bowel Dis       Date:  2009-02       Impact factor: 5.325

Review 4.  The future of molecular approaches to inflammatory bowel disease.

Authors:  Boyko Kabakchiev; Smita Halder; Mark S Silverberg
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 5.  The use of prognostic factors in inflammatory bowel diseases.

Authors:  Thomas Billiet; Marc Ferrante; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2014-11

6.  Evaluation of upper and lower gastrointestinal histology in patients with ileal pouches.

Authors:  Yinghong Wang; Ana E Bennett; Hui Cai; Lei Lian; Bo Shen
Journal:  J Gastrointest Surg       Date:  2011-11-04       Impact factor: 3.452

Review 7.  Surgical prophylaxis of pouchitis in ulcerative colitis.

Authors:  Giuseppe Brisinda; Serafino Vanella; Venanzio Valenza; Anna Crocco; Germano Perotti; Daniela Di Giuda; Giorgio Maria
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

8.  Diagnosis and management of postoperative ileal pouch disorders.

Authors:  Bo Shen
Journal:  Clin Colon Rectal Surg       Date:  2010-12

9.  Diagnosis and treatment of pouchitis.

Authors:  Bo Shen; Bret A Lashner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-05

Review 10.  Pouchitis.

Authors:  En-Da Yu; Zhuo Shao; Bo Shen
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.